POINT Biopharma Global Inc. (NASDAQ:PNT) Given Consensus Recommendation of “Hold” by Brokerages
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokerages that have covered the stock in the […]
More Stories
Perplexity AI Wants to Buy Google Chrome for $34.5 Billion!
A young artificial intelligence company called Perplexity AI has surprised the tech world by offering $34.5 billion to buy Google...
White House Orders Review of Smithsonian Exhibits Ahead of Nation’s 250th Birthday
By Victoria Friedman The White House on Tuesday ordered an internal review of selected Smithsonian museums and exhibitions to ensure...
Mexico Extradites 26 Alleged Cartel Members to US
By Aldgra Fredly Mexico extradited 26 alleged cartel members to the United States on Aug. 12, including high-ranking members of...
Federal Policing Takes Effect in Washington—What to Know
By Joseph Lord On Aug. 12, National Guard troops arrived in Washington after President Donald Trump federalized policing, citing a...
Chicago Partners Investment Group LLC Sells 837 Shares of Guidewire Software, Inc. (NYSE:GWRE)
Chicago Partners Investment Group LLC decreased its position in shares of Guidewire Software, Inc. (NYSE:GWRE – Free Report) by 42.8%...
Chinese Stocks To Add to Your Watchlist – August 10th
Duolingo, Wynn Resorts, and Mettler-Toledo International are the three Chinese stocks to watch today, according to MarketBeat’s stock screener tool....